TY - JOUR
T1 - The possible existence of occult metastasis in patients with ovarian clear-cell carcinoma who underwent complete resection without any residual tumours
AU - Kajiyama, Hiroaki
AU - Suzuki, Shiro
AU - Yoshihara, Masato
AU - Nishino, Kimihiro
AU - Yoshikawa, Nobuhisa
AU - Utsumi, Fumi
AU - Niimi, Kaoru
AU - Mizuno, Mika
AU - Kawai, Michiyasu
AU - Oguchi, Hidenori
AU - Mizuno, Kimio
AU - Yamamuro, Osamu
AU - Nagasaka, Tetsuro
AU - Shibata, Kiyosumi
AU - Kikkawa, Fumitaka
N1 - Publisher Copyright:
© Kajiyama et al.
PY - 2018
Y1 - 2018
N2 - The objective of this study was to estimate the frequency of possible occult metastasis through long-term survival analyses in patients with clear cell carcinoma (CCC) who had undergone complete resection. During the period of 1990-2015, 799 patients with stage I-IV CCC were identified in the TOTSG database. Of these, a total of 528 patients without a residual tumor were enrolled in the study and classified into four groups: Group 1: FIGO stage IA-IB (N=104), Group 2: FIGO stage IC1 (N=170), Group 3: FIGO stage IC2/IC3 (N=98), and Group 4: FIGO stage II-III (no residual tumor: N=156). Cumulative incidences of recurrence (CIR) and death (CID) were examined. The median age was 54, ranging from 29-87. The 5-year CIR / CID of each group were as follows: Group 1 (7.3% / 3.8%), Group 2 (14.3% / 10.2%), Group 3 (37.7% / 18.4%), and Group 4 (46.5% / 33.8%), respectively (P < 0.0001 (recurrence) / P < 0.0001 (death)). Furthermore, confining analysis to relapsed patients, 1-, 2-, and 3-year CID after recurrence were 41.5, 60.9, and 73.9, respectively. Confining analyses to patients with sufficient information about adjuvant chemotherapy, the 5-year CIR / CID of stage IA-IC1 patients with or without chemotherapy were as follows: recurrence (13.0% (yes) / 9.6% (no)), death (9.3% (yes) / 4.2% (no)), respectively (P=0.947 (CIR) / P=0.224 (CID)). CCC patients staged greater than IC2/ IC3 show a marked risk of mortality, even after complete surgical resection.
AB - The objective of this study was to estimate the frequency of possible occult metastasis through long-term survival analyses in patients with clear cell carcinoma (CCC) who had undergone complete resection. During the period of 1990-2015, 799 patients with stage I-IV CCC were identified in the TOTSG database. Of these, a total of 528 patients without a residual tumor were enrolled in the study and classified into four groups: Group 1: FIGO stage IA-IB (N=104), Group 2: FIGO stage IC1 (N=170), Group 3: FIGO stage IC2/IC3 (N=98), and Group 4: FIGO stage II-III (no residual tumor: N=156). Cumulative incidences of recurrence (CIR) and death (CID) were examined. The median age was 54, ranging from 29-87. The 5-year CIR / CID of each group were as follows: Group 1 (7.3% / 3.8%), Group 2 (14.3% / 10.2%), Group 3 (37.7% / 18.4%), and Group 4 (46.5% / 33.8%), respectively (P < 0.0001 (recurrence) / P < 0.0001 (death)). Furthermore, confining analysis to relapsed patients, 1-, 2-, and 3-year CID after recurrence were 41.5, 60.9, and 73.9, respectively. Confining analyses to patients with sufficient information about adjuvant chemotherapy, the 5-year CIR / CID of stage IA-IC1 patients with or without chemotherapy were as follows: recurrence (13.0% (yes) / 9.6% (no)), death (9.3% (yes) / 4.2% (no)), respectively (P=0.947 (CIR) / P=0.224 (CID)). CCC patients staged greater than IC2/ IC3 show a marked risk of mortality, even after complete surgical resection.
KW - Clear-cell carcinoma
KW - Epithelial ovarian carcinoma
KW - Metastasis
KW - Recurrence
UR - http://www.scopus.com/inward/record.url?scp=85040648900&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040648900&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.23921
DO - 10.18632/oncotarget.23921
M3 - Article
C2 - 29464073
AN - SCOPUS:85040648900
SN - 1949-2553
VL - 9
SP - 6298
EP - 6307
JO - Oncotarget
JF - Oncotarget
IS - 5
ER -